Help build the BPC-157 evidence record medicine has been missing.
The National BPC-157 Physician Research Collaboration is recruiting clinicians to help create a protocol-aligned, de-identified, publication-grade evidence stream—rather than another disconnected collection of anecdotes.
01Clinical interest is ahead of clinical evidence. Meaningful publication requires defined populations, comparable endpoints, planned follow-up, and an auditable safety record—not isolated before/after stories.
02Early contributors help shape the record. Participating investigators may contribute to a protocol-defined evidence collaboration, with contribution recognition and authorship eligibility governed by the final publication policy.
03Comparable multi-site data is more useful. A shared protocol, timepoint structure, marker plan, and de-identification boundary make site-level observations analyzable together.
The opportunity: join an investigator network built to convert responsible, protocol-defined human observations into a durable scientific record. This is not a promise of efficacy, a treatment directive, or an already-open patient trial.
Protocol layer
Versioned evidence context
Investigator materials, evidence context, and research procedures—not participant data.
peptideprotocol.wiki
Intelligence layer
DNA + RNA provenance
DNA collection, RNA-expression workflow, and assay/panel/QC/analysis provenance.
geneos.app
Study layer
De-identified research record
Analytics, checklists, structured exports, and manuscript-ready publication artifacts.
hyjournal.app
Why a molecular BPC-157 evidence record matters
BPC-157 is a 15-amino-acid peptide with a large preclinical literature and fragmented human observation. This collaboration is designed to turn that gap into a comparable, longitudinal human evidence record rather than another collection of one-off stories.
01 · BASELINE
DNA + RNA context
GeneOS creates a token-scoped DNA collection and RNA-expression baseline. The deterministic transcriptomic genetic intelligence engine preserves assay, panel, QC, and analysis version so pathway context stays traceable without exposing participant identity to the research record.
02 · FOLLOW-UP
Serial biomarker deltas
The final protocol locks baseline and follow-up timepoints, outcomes, adverse-event capture, and prespecified biomarker fields. It can examine longitudinal change across inflammatory, metabolic, endothelial, extracellular-matrix/remodeling, and safety-marker domains—not one isolated snapshot.
03 · REVIEW
Built for scientific scrutiny
hyJournal preserves protocol hash, token-scoped provenance, assay/analysis version, and structured exports. The investigator group can compile a reproducible evidence package for submission to multiple peer-reviewed journals once the readiness gates are complete.
From molecular baseline to peer review
Each consent-authorized, de-identified record is linked to the same protocol-defined marker plan and timepoint structure. That creates an auditable multi-site dataset that can be analyzed, reviewed, cited, and prepared for independent journal evaluation.
The GeneOS kit path: DNA collection + RNA-expression analysis
For pilot participation, order the GeneOS Ribosome Expression Test through the GeneOS store. It provides the DNA collection workflow, prepaid return process, and the ribosomal RNA-expression analysis used to prepare the protocol-defined marker package.
1
Order through GeneOS
Open the GeneOS kit store using the pilot link. The order flow captures the shipping details required to send the collection kit and prepaid return materials.
2
Use PILOT
Enter PILOT in the Referral Code field before completing checkout. Eligible pilot orders receive the active study discount; checkout displays the final total.
3
Receive token + QR
After payment confirmation, GeneOS issues the kit’s 32-character access token and QR code. Keep them with the kit workflow materials.
4
Collect, return, then connect
Follow the included collection instructions and prepaid return process. Use the approved study workflow before any participant enrollment activity.
How the GeneOS token protects the research workflow
AB12CD34 EF56GH78 …
One token. One kit-and-results access path.
GeneOS creates a unique 32-character token after payment confirmation and delivers it with a QR code. It supports access to the kit workflow, GeneOS wizard, console, and results across devices. It is confidential and is not a participant’s name, medical record number, or consent record.
Clinic responsibilities
Retain the local identity map, informed-consent record, and source documentation.
Use only the final protocol, approved timepoints, and defined marker plan.
Submit consent-authorized, de-identified values and approved research provenance.
What the collaboration provides
Physician-network activation after review.
Protocol and evidence materials through PeptideProtocol.wiki.
GeneOS assay/panel/QC/analysis provenance and hyJournal research infrastructure.
Clinician participation checklist
For every protocol-defined case, the clinician retains the local identity and consent file. hyJournal receives the consent-authorized, de-identified research record below.
✓Activate your investigator profileSubmit clinician/site details, research role, and the approved protocol version used by your practice.
✓Link the GeneOS tokenEnter the confidential kit token and assay/provenance details—not a participant name, MRN, or local identity map.
✓Record the baselineEnter protocol-defined eligibility context, target outcomes, relevant medications/co-interventions, and baseline biomarker values with source and date.
✓Capture DNA/RNA marker contextAttach the approved GeneOS DNA/RNA marker package, panel/version, quality-control status, and analysis provenance.
✓Enter follow-up changesSubmit the same defined outcomes and biomarker fields at protocol timepoints, including adverse events and discontinuations.
✓Contribute to the review packagehyJournal aggregates the de-identified structured record for analysis, evidence export, and the multi-journal peer-review submission package.
